drugset / Trial / NCT04762186
Viable Human SARS-CoV-2 Specific T Cell Transfer in Patients at Risk for Severe COVID-19
Phase 1
Terminated
1 enrolled
University Hospital Cologne
Hannover Medical School · collabMiltenyi Biomedicine GmbH · collabZKS Köln · collab
NaSequentialOpen-labelTreatment
Summary
Monocentric open phase I (dose escalation component), followed by a multi-center, randomized, phase II component benchmarking IMP+SoC against SoC
Timeline
- Start
- 2021-12-08
- Primary completion
- 2022-08-03
- Completion
- 2022-08-03
Outcome
Outcome not reported
Stopped (Enrollment): “poor recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | human SARS-CoV 2 specific T lymphocytes | Cell therapy | 1000 cells/kg | Other |
| Subject | human SARS-CoV 2 specific T lymphocytes | Cell therapy | 5000 cells/kg | Other |
Indications
No indication recorded.